Role of epoetin in the management of anaemia in patients with lung cancer

Lung Cancer

Volumn 46, Issue 2, 2004, Pages 149-156

  Morère, Jean François ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Anaemia; Anaemia prevention; Epoetin; Haemoglobin; Lung cancer; Platinum based chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE;

ANEMIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING;

ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; SURVIVAL;

EID: 4944232216     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.034     Document Type: Review

References (62)

1. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 91:1999;1616-1634
2. Scagliotti G.V., Novello S. Role of erythropoietin in the treatment of lung cancer associated anaemia. Lung Cancer. 34:2001;S91-S94
3. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin. Oncol. 25(Suppl 7):1998;43-46
4. Curt G.A., Breitbart W., Cella D., et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. The Oncologist. 5:2000;353-360
5. Stone P., Richardson A., Ream E. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann. Oncol. 11:2000;971-995
6. Caro J.J., Salas M., Ward A., et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 91:2001;2214-2221
7. Depierre A., Lagrange J.L., Theobald S., et al. Standards, options and recommendations for the management of non small cell lung carcinoma. Bull. Cancer. 90:2003;151-166
8. Langer C.J., Choy H., Glaspy J.A., et al. Standards of care for anemia management in oncology. Focus on lung cancer. Cancer. 95:2002;613-623
9. Del Mastro L., Gennari A., Donati S. Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia. Ann. Oncol. 10(Suppl 5):1999;S91-S94
10. Schiller J., Harrington D., Sandler A., et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc. ASCO. 19:2000;A2
11. Goto K., Nishiwaki Y., Takada M., et al. Final results of a phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (P) and etoposide (E) for limited-stage small cell lung cancer (LD-SCLC): the Japan Clinical Oncology Group (JCOG) Study. Proc. ASCO. 18:1999;A1805
12. Harrison L.B., Shasha D., White C., Ramdeen B. Radiotherapy-associated anemia: the scope of the problem. Oncologist. 5(Suppl. 2):2000;1-7
13. Hollen P.J., Gralla R.J., Kris M.G., et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur. J. Cancer. 29A(Suppl 1):1993;S51-S58
14. Tanaka K., Akechi T., Okuyama T., et al. Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. J. Pain Symptom Manage. 23:2002;417-423
15. Crawford J., Cella D., Cleeland C.S., et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 95:2002;888-895
16. Robnett T.J., Machtay M., Hahn S.M., et al. Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients. Cancer J. 8:2002;263-267
17. Albain K.S., Crowley J.J., LeBlanc M., et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J. Clin. Oncol. 9:1991;1618-1626
18. MacRae R., Shyr Y., Johnson D., et al. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother. Oncol. 64:2002;37-40
19. Hansen O., Baekke J., Hansen K.H., et al. The need for transfusion of packed red blood cells in palliative chemotherapy with carboplatin and vinorelbine in advanced NSCLC when no erythropoietin is used. Lung Cancer. 41(Suppl. 2):2003;S91(AP-1)
20. Østerlind K., Andersen P.K. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 46:1986;4189-4194
21. Oehler W., Fischer J., Merkle K. Does the initial hemoglobin value modify the primary tumor reaction? A study of 264 irradiated bronchial cancers. Radiobiol. Radiother. (Berl). 31:1990;325-331
22. Jazieh A.R., Hussain M., Howington J.A., et al. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann. Thorac. Surg. 70:2001;1168-1171
23. Burkes R.L., Card C.M., Ginsberg R.J., et al. Anaemia as a prognostic factor in induction chemotherapy for stage IIIA N2 non small cell lung cancer (NSCLC). Lung Cancer. 41(Suppl. 2):2003;S156. (abstract P-253)
24. Zarogoulidis K., Papagiannis A., Ziogas E., et al. Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer. Eur. J. Cancer. 33:1997;2428-2431
25. Teicher B.A., Holden S.A., al-Achi A., et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 50:1990;3339-3344
26. Brizel D.M., Dodge R.K., Clough R.W., et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53:1999;113-117
27. Barrett-Lee P.J., Bailey N.P., O'Brien M.E., et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br. J. Cancer. 82:2000;93-97
28. Walker R.H. Special report: transfusion risks. Am. J. Clin. Pathol. 88:1987;374-378
29. Goodnough L.T., Brecher M.E., Kanter M.H., et al. Transfusion medicine. First of two parts - blood transfusion. N. Engl. J. Med. 340:1999;438-447
30. Ludwig H., Fritz E., Kotzmann H., et al. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 322:1990;1693-1699
31. Hyman N.H., Foster R.S. Jr., DeMeules J.E., et al. Blood transfusions and survival after lung cancer resection. Am. J. Surg. 149:1985;502-507
32. Österborg A., Brandberg Y., Molostova V., et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J. Clin. Oncol. 20:2002;2486-2494
33. Cazzola M., Beguin Y., Kloczko J., et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin deficiency. Br. J. Haematol. 122:2003;386-393
34. Glaspy J., Bukowski R., Steinberg D., et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol. 15:1997;1218-1234
35. Demetri G.D., Kris M., Wade J., et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol. 16:1998;3412-3425
36. Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19:2001;2865-2874
37. Boogaerts M., Coiffier B., Kainz C. Epoetin β QOL working group. Impact of epoetin beta on quality of life in patients with malignant disease. Br. J. Cancer. 88:2003;988-995
38. Hardut D., Wiesenberger K., Minar W., et al. Epoetin beta in patients with lung cancer receiving chemotherapy. Lung Cancer. 41(Suppl. 2):2003;S264. (AP-6821)
39. Vansteenkiste J., Pirker R., Massuti B., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl. Cancer Inst. 94:2002;1211-1220
40. Crawford J., Demetri G.D., Gabrilove J.L., et al. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin. Lung Cancer. 3:2002;180-190
41. Gabrilove J.L., Cleeland C.S., Livingston R.B., et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in Hb and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 19:2001;2875-2882
42. Hansen O., Nielsen M., Werenberg K.A., et al. The impact of hemoglobin (Hb) value on the outcome of radical radiotherapy (RT) in locally advanced NSCLC. Lung Cancer. 41(Suppl 2):2003;S136. (AP-180)
43. Shannon AM, Bouchier-Hayes DJ, Toomey D. Erythropoietin enhances the antitumour efficacy of a cisplatin and gemcitabine chemotherapy regime in a murine model of Lewis lung carcinoma. In: Proceedings of AACR 2004;A2210.
44. Kunikane H., Watanabe K., Fukuoka M., et al. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int. J. Clin. Oncol. 6:2001;296-301
45. Crawford J., Robert F., Perry M., et al. Epoetin alfa 40,000 u once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy. Proc. ASCO. 22:2003;628(A2527)
46. Lee S.L. The use of erythropoietin in radiation oncology. Cancer Control. 5(Suppl. 1):1998;33-40
47. Thatcher N., De Campos E.S., Bell D.R., et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br. J. Cancer. 80:1999;396-402
48. Dunphy F.R., Harrison B.R., Dunleavy T.L., et al. Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy. Cancer. 86:1999;1362-1367
49. de Campos E., Radford J., Steward W., et al. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J. Clin. Oncol. 13:1995;1623-1631
50. Portalone L., Altieri A.M., Antilli A., et al. Preventative epoetin a (EPO) use in the treatment of advanced nsclc: an AIPO oncology study group multicenter trial. Eur. J. Cancer. 37(Suppl 6):2001;S56(A196)
51. Oberhoff C., Neri B., Amadori D., et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann. Oncol. 9:1998;255-260
52. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;705-715
53. Henke M., Laszig R., Rübe C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet. 362:2003;1255-1260
54. Leyland-Jones B. BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4:2003;459-460
55. Leyland-Jones B., Mahmud S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 363:2004;80
56. Kaanders J.H.A.M., van der Kogel A.J. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 363:2004;78-79
57. Haddad R., Posner M. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 363:2004;79
58. Blumberg N., Heal J.M. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 363:2004;80
59. Beggs V.L., Disalvo W.M., Meyer L.P., et al. Fatigue and plasma cytokines in a randomized double-blind placebo-controlled trial of epoetin alfa in patients undergoing combined modality therapy for unresectable non-small cell lung cancer (NSCLC). Proc. ASCO. 22:2003;733(A2984)
60. Casas F., Vinolas N., Ferrer F., et al. Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 55:2003;116-124
61. Pirker R., Gateley J., Tomita D., Rossi G., Musil J. Results of a phase 3, randomized, double-blind study indicate that darbepoetin alfa decreases RBC transfusions and increases health-related quality of life in comparison with placebo. Hematol. J. 3(Suppl. 1):2002;352(1189)
62. Bohlius J.F., Langensiepen S., Schwarzer G., Bennett C.L., Engert A. Does erythropoietin improve overall survival in the treatment of patients with malignant diseases? Results of a comprehensive meta-analysis. Blood. 102:2003;A709